Clinical Trial Update: Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) [Phase 3]

View source ↗

Summary

Extension study update for participants in Phase 3 trials of Belzutifan (MK-6482-043 / LITESPARK-043) with ongoing recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• Belzutifan (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Von Hippel-Lindau Disease, Carcinoma, Renal Cell | Phase 3 | Status: RECRUITING